Corporate Banner
Satellite Banner
Technology Networks Header
Sunday, November 23, 2014
Technology Networks
 
Register | Sign in
Home Page
  Terms & Conditions


Press Releases & Product Announcements

Please send all press releases and product announcements to pr@technologynetworks.com Wherever possible, press releases should be emailed as a Microsoft Word attachment or embedded in the email itself. Images should be sent as separate attachments. Where possible please insert the name(s) of the community(ies) that you wish the press release to be published on into the subject line of the email.

For a full list of all Technology Networks’ communities please click here

Submitting Application Notes

By submitting your application notes to us for online publication you are agreeing to the Terms and Conditions for the application notes section of Technology Networks' communities and, confirming that you have the required copyright to submit these application notes.

Application notes should be submitted to apps@technologynetworks.com preferably as a PDF, if not as a Microsoft Publisher or PowerPoint file. A 40 - 70 word summary must be sent with each application note submitted.

The name(s) of the website(s) that you wish the application note to be published on should be entered into the subject line of the email. For a full list of all Technology Networks’ communities please click here

Before submitting an application note for online publication please read the terms and conditions below.

Submitting a Poster

Posters submitted by academics and from not-for-profit organizations will be published free of charge. For commercial companies there will be an administration charge of $200 for each poster published. Please contact Kelly Giles for more information.

By submitting your poster to us for online publication you are agreeing to the Terms and Conditions for the Posters section of Technology Networks' communities and confirming that you have the required copyright to submit these posters.

Posters should be submitted using the online submission form which is located within the posters section of each website, (click “submit poster” link). The poster needs to be submitted as a PDF or Microsoft PowerPoint file. A 40 – 70 word summary must be submitted along with the poster.

If you have any problems with you submission, please contact posters@technologynetworks.com, stating the name of the website you wish to publish your poster on in the subject line.

Before submitting a poster for online publication please read the terms and conditions below.

TERMS AND CONDITIONS

1. Services / Consideration.
Technology Networks Ltd. ('TechNet') shall develop an electronic version of the printed Application Note or Poster that has been created from the files provided by you (the 'Author'). In consideration of TechNet's development, archiving and retrieval of the Author's Application note, Author shall: (a) grant the license stated in Section 3.

2. Copyright Ownership.
As between TechNet and Author, Author shall be the owner of all copyrights in and to the content contained in the Print Application Note or poster and the online Application Note or Poster.

3. Copyright License.
In order for TechNet to electronically archive, display and distribute the Application Note or Poster, Author hereby grants to TechNet an irrevocable, perpetual license to maintain, store, cache, copy and distribute (in any current or future media) the Application Note or Poster (the 'License Grant'). The License Grant includes TechNet's right to include the Application Note or Poster in its current and future database or databases as well as to distribute the Application Note or Poster electronically to third parties through any one or more websites operated by or on behalf of TechNet.

4.Representations and Warranties.
Author hereby represents and warrants to TechNet that: (i) Author is the owner or authorized licensee of all right, title and interest (including all copyrights and other intellectual property rights) in and to all content that appears on the Application Note or Poster; (ii) all content that appears in the Application Note or Poster is the Author's original work and contains no libelous or unlawful statements, does not infringe on the rights or privacy of others or contain material or instructions that might cause harm or injury, (iii) Author's execution and performance of this Agreement does not and shall not constitute a breach of, or otherwise violate, any written or verbal understanding or agreement between Author and any third party; and (iv) TechNet's use of the files provided by the Author to create the Application Note or Poster, as well as TechNet's exercise of its rights pursuant to the License Grant, shall not infringe or violate the copyrights, or other intellectual property rights, of any third party.

5.Miscellaneous.
(a) This Agreement shall be construed and enforced in accordance with the laws of the United Kingdom. Each party hereby consents to the exclusive jurisdiction and venue of any court located in the United Kingdom with respect to any claim or controversy arising out of or related to this Agreement.

(b) This Agreement: (i) shall benefit and bind each party and their successors and assigns; (ii) contains the entire understanding and agreement of the parties; and it incorporates or supersedes all other written or verbal agreements and understandings with respect to the subject matter; and (iii) may be amended or modified only in writing signed by both parties and referring specifically to the Agreement.

Scientific News
Themis Bioscience’s Vaccine Against Chikungunya Successful in Phase 1
Results presented at international conferences in Philadelphia and New Orleans.
Anti-Leukemia Drug May Also Work Against Ovarian Cancer
An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer – and likely other cancers as well.
Novel Cancer Vaccine Approach for Brain Tumors
Researchers unravel the mechanisms behind a novel cancer vaccine for brain tumors, paving the way for further development.
Almac Announces Launch of CLIA Validated Next Generation Sequencing Assay
P53 considered important biomarker for cancer drug discovery.
Classification of Gene Mutations in Neuroblastoma
Penn Medicine and CHOP experts define riskier mutations in neuroblastoma, setting stage for clinical trial.
New Vaccine Generates Strong Immune Response Against Hepatitis C
A new hepatitis C vaccine has shown promising results in an early clinical trial at Oxford University, generating strong and broad immune responses against the virus causing the disease.
Immune Booster Helps Improve Survival In Metastatic Melanoma
Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer – a median 17.5 months vs. 12.7 months – if they simultaneously received an immune stimulant.
Protecting us from Our Cells
Growth factor boosts natural defence against auto-immune disorders.
TxCell Achieves Positive Results for Col-Treg in a Model of Autoimmune Uveitis
TxCell set for phase I/II proof of principle clinical study in Q2 2015 for its second therapeutic candidate in this rare eye disease.
NIH Begins Early Human Clinical Trial of VSV Ebola Vaccine
Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health’s Clinical Center in Bethesda, Maryland.
Scroll Up
Scroll Down
SELECTBIO
SELECTBIO Market Reports
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv